Log in
The University of Southampton's lifecourse cohort studies have led to a paradigm shift in the medical approach to obesity and non-communicable diseases. Research linking maternal pre-conception and early years nutrition with health outcomes for later life has directly influenced public healthcare policy at international (United Nations), national (Scientific Advisory Committee on Nutrition) and local (Southampton City) levels. Dissemination through medical practice and Southampton-designed public education programmes such as LifeLab means this research has already led to health benefits for tens of thousands of people, providing them with the information and tools to help prevent themselves and their children from succumbing to a non-communicable disease.
Novel research into the cardiovascular and other health benefits of consuming flavanol-containing foods at the University of Reading prompted a multi-national food and confectionary producer, Mars Incorporated, to invest over £1.1 million in research into the absorption, metabolism and health effects of cocoa-derived flavanols in humans. This research informed the development of a cocoa-extract supplement drink and supplement extract, both widely available in the US since 2010. This in turn sparked interest from other multinational corporations looking to market flavanol- and other flavonoid-containing health products, resulting in an additional £917K investment by industry. Mars' cocoa-extract supplements currently hold a 1% share of all food and drinks marketed on a cardiovascular health platform in the US; a market worth US$3.1 billion in 2012. Research by Reading and others has provided evidence that consumption of these products can improve memory and cognition, cardiovascular health and digestive health for consumers. These and other research findings have been widely disseminated to the general public by the Reading researchers.
Strathclyde research underpinned formation of the Scottish Chikhwawa Health Initiative (SCHI) in 2006, to deliver tangible health benefits by reducing major causes of disease and death in Chikhwawa, Malawi. Health impact occurred through training of government personnel and community volunteers, combined with increased infrastructure capacity, at health facilities and in the community, producing improvements in water quality, sanitation and communicable disease control. Within the first 2 years of implementation among a population of 5700 people, a 30% reduction in diarrhoeal disease was achieved, and access to safe water improved through increased water points and improved water storage [1]. Initial success saw expansion of the initiative to 150 communities covering a population of 110,000.
Our biomarker research and underpinning technologies have commercially impacted upon the global R&D strategies of Unilever, Philips and Mars, realising new market areas for them, resulting in several million GBP invested in related R&D as well as "claim support" for products both in development and already available on shelves. Unilever have adopted biomarker outcomes as endpoints in clinical trials of new products, and Philips and Mars are developing with us saliva-based near-patient diagnostic tests for the human and small animal markets. We have also spun out two SME's: A) Oral Health Innovations (OHI) Ltd has developed online risk and disease analysis software for oral conditions, which was piloted, adopted and launched by Denplan, the UKs largest dental capitation plan operator (accessing 6500 dentists and 1.8 million patients), at the 2013 annual British Dental Association conference; and B) GFC Diagnostics makes SmokeScreen™ a non-invasive, sensitive and objective saliva test developed from our biomarker research at Birmingham University. Both technologies have already provided demonstrable social and commercial impact and given their uptake to date, will also deliver economic, environmental and health impacts.
Clinical research conducted at the UCL Institute of Child Health between 1998 and 2011 under the direction of Professors Alan Lucas and Atul Singhal showed that a slower rate of infant weight gain had long-term benefits to reduce the risk of obesity and cardiovascular disease. This contradicted the accepted view, which favoured the promotion of rapid weight gain in infancy. This work has had a significant influence on public health policies and initiatives in the UK and elsewhere. It has changed the way infant formulas are made and used. Two new interventions for overweight children have been developed and are helping families around the world.
Research conducted at the University of Bristol between 2003 and 2012 on the ecology, epidemiology and control of parasitic flies and worms has improved animal health and welfare in the UK and is addressing a major constraint on global food production — animal disease, particularly in the context of climate change. These are some of the impacts:
A discovery that a tomato extract could help with healthy blood flow has been translated into a functional food ingredient now marketed globally via the spin-out company Provexis plc. Fruitflow® — Provexis' lead product — is the result of findings by researchers at the Rowett Institute of Nutrition and Health, now part of the University of Aberdeen, that biologically active constituents in tomatoes inhibit blood platelet aggregation: a known cause of heart attack, stroke and venous thrombosis. In 2009 Fruitflow® was the first food ingredient to meet the requirements of the European Food Safety Agency for products with a specific health claim. Provexis — the University of Aberdeen Rowett Institute spinout — is listed on the AIM market — the London Stock Exchange's international market for smaller growing companies — has seen values of £14 - £60 million and secured co-development agreements with major international partners, including DSM, Unilever and Coca-Cola. This case study demonstrates the direct translation of research to produce a functional food ingredient of interest to global market players.
The claimed impact therefore relates to development of new product, which has received the first ever novel health claim (Article 13.5) from the European Food Safety Authority, and is being marketed as novel food ingredient globally by a multinational company.
Building on work which has contributed, via NICE guidance, to £1 billion in annual savings to the NHS in its healthcare provision for osteoporotic fractures in older adults, research at the £14.4 million MRC Lifecourse Epidemiology Unit (LEU), University of Southampton, has inspired the world's first randomised controlled trial of vitamin D supplementation versus placebo in pregnancy. This work was designed to provide a definitive answer to the question of whether supplementing pregnant women with vitamin D leads to increased bone mineral accrual in the offspring. This work has also shaped national and international guidance on vitamin D supplementation both during pregnancy and in older age; Southampton's programme of osteoporosis research has attracted £10 million in research funding from health organisations and the EU.
Caffeine is widely consumed in pregnancy as has the potential to harm the developing fetus. Professor Janet Cade and colleagues at the University of Leeds designed a robust study to accurately quantify caffeine intake in 2635 pregnant women throughout pregnancy. The results showed caffeine intake is associated with an increased risk of fetal growth restriction, which is linked with perinatal mortality and morbidity and adverse effects in later life. As a result of this study, and a review of previous evidence, the Food Standards Agency issued new advice to pregnant women to limit their daily caffeine intake to below 200mg/day.
Our impact has been to protect the public by informing and influencing both the international policy debate on health claims associated with soy consumption, and the relevant regulatory risk assessment authorities.
Our research formed a key component of dossiers that resulted in the rejection of health claims by the European Food Safety Authority (EFSA, the EU agency responsible for the scientific substantiation of health claims) relating to soy isoflavones and a number of health endpoints including bone health, heart health and menopausal symptoms. Earlier work had underpinned decisions on comparable health claims in the US and UK.
Our soy isoflavone research also provided key scientific data on the absorption of isoflavones by the body (and dependence on age and food source) to the UK Government Committee on Toxicity (COT) policy review on the toxicity of chemicals with a specific focus on soy infant formula. This expands on COT advice in 2003, which used earlier Cassidy research and helped to inform the UK government's (Food Standards Agency) research programme on phytoestrogens /isoflavones.